Date
Aug 30, 2023
Attendees
Nick Decker
Gyan Penrose-Kafka
Hubert Vesper
Rebecca McNall
Dr. Hung Luu (guest)
Robert Rae
Xavier Gansel
Goals
Initial scoping discussion
Align on what we intend first deliverable(s) to be
Discussion topics
Time | Item | Presenter | Notes |
---|---|---|---|
5 | Welcome | All | |
30 | Perspectives chat: Dr. Luu | All | Perspectives (Dr. Luu): Need for accurate coding so that we can use results from real patients. Use for research, regulatory clearance, reporting to agencies.
The team discussed what our deliverable is out of this team. Need to reference MDIC framework on our WG page. Deliverables:
|
Next Steps |
Next call in two weeks…main agenda item will be to go through proposed use cases |
Action items
Quick decisions not requiring context or tracking
For quick, smaller decisions that do not require extra context or formal tracking, use the “Add a decision…” function here.
Proposed Use Cases:
Use Case | Detail | Your name | Comments / Discussion |
---|---|---|---|
Broaden description beyond EUA transitions. | Suggest broadening the description to include RWE to supplement 510(k)s or PMAs (reduce burden or help bridge studies, lots of examples that have got FDA approval this way) and RWE to support claims expansion (e.g. new specimen type) for 510(k) or PMA devices. | Gyan Penrose-Kafka | There are examples of using RWE to generate evidence that can go through EUA, but how is it envisioned that an IVD Data Hub makes this better, higher quality, etc.? |
Instrumentation and Ancillaries | what instrumentation an assay is run on, that would be really helpful. I am not sure it is possible to collate specimen collection kit/swab/collection device but I can see scenarios where that could help expand claims. | Gyan Penrose-Kafka | Data could come from LIDR or from the device itself…discussion in white paper about sourcing data |
Public Health Reporting | The ability for the organization that houses the data hub to be able to report results on behalf of laboratories to local, state and federal public health agencies | Rob Rae | |
Research | The ability to use the data hub data for clinical research | Rob Rae | |
Research | Use the data hub data for post-market surveillance (may also help with claims extension) or clinical utility studies | Yue Jin | |
Innovation | Site / patient identification for enrollment in clinical studies - supportive of increasing diversity in clinical trials | Nick Decker | |
infrastructure | enable a decentralized approach enabling local usage of the data hub (i.e. at the source of production) for local needs as well as global usage accros all sites using a CDM & vocabularies | Xavier Gansel | this may translate into a federated nature for the IVD data hub, associating lab data & some relevant patient data. |